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Development of a Smartphone-Enabled Hypertension and Diabetes
Mellitus Management Package to Facilitate Evidence-Based Care
Delivery in Primary Healthcare Facilities in India: The mPower Heart
Project
Vamadevan S. Ajay, MPH, DLSHTM, PhD; Devraj Jindal, BDS, MPH; Ambuj Roy, MD, DM; Vidya Venugopal, MS, PhD; Rakshit Sharma, MBA;
Abha Pawar, BDS, MPH; Sanjay Kinra, MD, MRCP, MSc, PhD; Nikhil Tandon, MD, PhD; Dorairaj Prabhakaran, MD, DM, MSc
Background-—The high burden of undetected and undertreated hypertension and diabetes mellitus is a major health challenge
worldwide. The mPower Heart Project aimed to develop and test a feasible and scalable intervention for hypertension and diabetes
mellitus by task-sharing with the use of a mobile phone–based clinical decision support system at Community Health Centers in
Himachal Pradesh, India.
Methods and Results-—The development of the intervention and mobile phone–based clinical decision support system was carried
out using mixed methods in ﬁve Community Health Centers. The intervention was subsequently evaluated using pre–post
evaluation design. During intervention, a nurse care coordinator screened, examined, and entered patient parameters into mobile
phone–based clinical decision support system to generate a prescription, which was vetted by a physician. The change in systolic
blood pressure, diastolic blood pressure, and fasting plasma glucose (FPG) over 18 months of intervention was quantiﬁed using
generalized estimating equations models. During intervention, 6797 participants were enrolled. Six thousand sixteen participants
had hypertension (mean systolic blood pressure: 146.1 mm Hg, 95% CI: 145.7, 146.5; diastolic blood pressure: 89.52 mm Hg,
95% CI: 89.33, 89.72), of which 3152 (52%) subjects were newly detected. Similarly, 1516 participants had diabetes mellitus
(mean FPG: 177.9 mg/dL, 95% CI: 175.8, 180.0), of which 450 (30%) subjects were newly detected. The changes in systolic blood
pressure, diastolic blood pressure, and FPG observed at 18 months of follow-up were 14.6 mm Hg (95% CI: 15.3, 13.8),
7.6 mm Hg (CI: 8.0, 7.2), and 50.0 mg/dL (95% CI: 54.6, 45.5), respectively, and were statistically signiﬁcant even
after adjusting for age, sex, and Community Health Center.
Conclusions-—A nurse-facilitated, mobile phone–based clinical decision support system-enabled intervention in primary care was
associated with improvements in blood pressure and blood glucose control and has the potential to scale-up in resource poor settings.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁers: NCT01794052. Clinical Trial Registry—India:
CTRI/2013/02/003412. ( J Am Heart Assoc. 2016;5:e004343 doi: 10.1161/JAHA.116.004343)
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H igh blood pressure and diabetes mellitus are majorcontributors to cardiovascular disease burden, a
leading cause of mortality worldwide and in India.1,2 A
systematic review estimated that among adults, 33.8% of
urban and 27.6% of rural population have hypertension in
India.3 Diabetes mellitus prevalence in India varies between
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10.9% and 14.2% and 3.0% to 8.3%, respectively in urban and
rural adults.4 Kearney et al estimated that the number of
persons with hypertension in India will rise from 118.2 mil-
lion in 2000 to 213.5 million in 2025, which constitutes an
80% rise.5 Similarly, the International Diabetes Federation
estimates that diabetes mellitus is likely to increase from
69.2 to 123.5 million by 2040.6 Multiple studies have
reported poor awareness, treatment, and control of these 2
conditions in India.3,7,8 For example, in India only a tenth of
the rural population and one ﬁfth of the urban population
with hypertension have their blood pressure under control.
Given these facts, achieving the global voluntary targets for
noncommunicable diseases (NCDs) by 2025 will be chal-
lenging for India unless access to care is expanded through
task shifting/sharing, greater use of technology, and evi-
dence-based care provision. We therefore developed and
tested a feasible and scalable intervention for hypertension
and diabetes mellitus care, incorporating task-sharing and a
mobile phone–based decision support software system
(mDSS) at Community Health Centers (CHCs) in the state
of Himachal Pradesh in India.
Methods
The study employed a mixed methods approach to design the
intervention, which was subsequently implemented and
evaluated at 5 primary care facilities using both qualitative
and quantitative methods.
The design phase included review of literature to
identify barriers for delivering care for hypertension and
diabetes mellitus in primary care settings in India.
Interventions to improve the process of care, including
mHealth-based clinical decision-support tools, were also
reviewed. Concurrently, a needs-assessment exercise was
carried out at the selected health facilities through a
Health Facility Assessment tool developed using the Indian
Public Health Standards for Community Health Centres.9
The facility assessment covered the 4 domains: service
delivery, personnel, equipment, and drugs in relation to
capacity for hypertension and diabetes mellitus care. In
addition to health facility assessment, in-depth interviews
with stakeholders in the healthcare organization (health
administrators, doctors, and nurses) were carried out.
Furthermore, observation of the functioning of the clinics
and assessment of the records of the health facility were
also made. We collated the inputs from literature review,
needs assessment exercise, in-depth interviews with
stakeholders, and consultations with domain experts
(cardiologists, endocrinologists, and health administrators)
to design the intervention. These inputs were used for
preparing training modules and mobile phone–based
clinical decision-support software tools (details of mDSS
development is described in the Results section) for the
healthcare team.
In order to implement the intervention, the Principal
Investigators (D.P. and N.T.) made a formal presentation
before the Government Ofﬁcials of the Himachal Pradesh. The
intervention, namely, “mPower Heart Project,” was approved
by the state government. As per the advice of the State
Government, Solan District was chosen for the project,
considering its better roads and mobile phone connectivity in
comparison to other districts. Subsequently, the Project
Coordinator (VSA) attended a monthly meeting of the health
department at the district headquarters, during which the
Chief Medical Ofﬁcer of the district introduced the project to
the Block Medical Ofﬁcers (Chief Medical Ofﬁcer of the CHCs)
in order to ensure full support and cooperation from the
health system.
Prior to commencing the mPower Heart Project, the
Medical Ofﬁcers and nurses of the CHCs were trained to
deliver the intervention, using the training modules, developed
centrally by the investigators (D.P., N.T., A.R.) and other
experts in the ﬁeld. In addition, to support the delivery of the
intervention, the district and state ofﬁcials were regularly
engaged to ensure availability of generic medicines recom-
mended by the Indian Public Health Standards in the local
pharmacies. During the evaluation phase of the mPower Heart
Project intervention in 5 CHCs, the following outcomes were
assessed:
1. Number of patients attending the outpatient clinic (Clinic)
eligible for opportunistic screening.
2. Number of known cases of hypertension/diabetes mellitus
attending the clinic.
3. Number of new cases of hypertension/diabetes mellitus
detected through opportunistic screening.
4. The mean change in systolic blood pressure (SBP),
diastolic blood pressure (DBP), and fasting plasma glucose
(FPG) up to the 18 months of follow-up.
Throughout the duration of the mPower Heart Project,
participants were advised to come back to the CHCs at 3-
month intervals for follow-up. Since the enrollment was a
continuous process throughout the intervention period, the
duration of follow-up varied across participants. The longest
follow-up data (18 months) were available for those enrolled
in the initial 3 months, while only baseline values were
available for those subjects who enrolled toward the end of
the intervention. We therefore decided to report the mean
level of outcomes for every follow-up until the 18th month of
the project period, at which time point we had adequate
follow-up data. Hence, for evaluating outcomes such as SBP,
DBP, and FPG, we considered 1 baseline visit and 6 follow-ups
(3, 6, 9, 12, 15, and 18 months of the project period) for the
analysis.
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Statistical Analysis
Continuous variables are reported as means along with their
conﬁdence intervals. Categorical variables are reported as
proportions. The change in SBP/DBP was examined among
those with a diagnosis of hypertension or hypertension and
diabetes mellitus, while the change in fasting blood glucose
was studied among those comorbid with both conditions or a
diagnosis of diabetes mellitus alone. Generalized estimating
equations models with an unstructured correlation structure
were used for the SBP analyses and an exchangeable
correlation structure was used for the fasting blood glucose
analyses.10 We used the Huber White sandwich estimator for
variance in the fasting blood glucose models in order to
address potential model misspeciﬁcation.11,12 The regression
models included binary indicators for each follow-up time
point so as to quantify the change in SBP and FPG at each
time point relative to the baseline. All models were adjusted
for age, sex, and CHC in order to examine the change in
clinical parameters after controlling of patient demographics.
As part of a secondary analysis, we examined results from
interaction models exploring the change in clinical parameters
over time, comparing those with new versus known diagnoses
of hypertension and/or diabetes mellitus. These models were
also adjusted for patient demographics and CHC. We also ﬁt
similar interaction models between disease diagnosis groups
(hypertension alone versus both hypertension and diabetes
mellitus; diabetes mellitus alone versus hypertension and
diabetes mellitus) and time in order to explore whether the
change in the clinical parameters over time differed by
disease diagnosis. All analyses were performed in STATA SE
Version 13.
Setting
The development and evaluation of the intervention was
carried out in 5 government CHCs in the Solan district located
in the north Indian state of Himachal Pradesh, India. The CHCs
were situated in the blocks, namely, Dharampur, Dharlagarh,
Syri, Kunihar, and Nallagarh. Each CHC catered to nearly
100 000 to 120 000 rural population. The CHCs were headed
by a Block Medical Ofﬁcer and had an additional 3 to 4
Medical Ofﬁcers, all trained in modern medicine. The clinics at
the CHCs catered to 80 to 200 patients each day.
Timeline of Project
The project started with a design phase, which commenced in
February 2012, seeking necessary approvals from the
government. The evaluation of the intervention was carried
out between December 1, 2012 and August 31, 2014. All
participants gave written informed consent and the study was
approved by the ethics committee of Centre for Chronic
Disease Control (CCDC), New Delhi and has been registered
with ClinicalTrials.gov (NCT01794052) and the Clinical Trial
Registry of India (CTRI/2013/02/003412).
Results
Design of the Intervention
The health facility assessment and the in-depth interviews
provided rich feedback for designing the intervention. The
critical gaps that were identiﬁed were insufﬁcient personnel at
the outpatient clinics of CHCs to provide care, lack of clarity/
knowledge and subsequent insufﬁcient use of clinical man-
agement guidelines, absence of educative tools to support
and standardize patient care, insufﬁcient supply of drugs, and
lack of adequate laboratory support to guide therapy. Based
on these inputs and consultations with experts, a 6-
component “m-Power Heart Project Intervention” was
designed that included the following:
1. A nurse care coordinator (NCC) to attend to individuals
with hypertension and diabetes mellitus at the clinics to
address the gap in personnel.
2. Structured training of the Medical Ofﬁcers and NCC about
the intervention.
3. Clinical management guideline for hypertension and
diabetes mellitus (Tables S1 and S2).
4. A mobile phone–based clinical decision-support software
(mDSS) tool for the healthcare team to input patient
demographics, history, and physical ﬁndings and to
generate an individualized prescription based on standard
clinical management guidelines.
5. Counseling services for patients on diet, tobacco, physical
activity, and compliance with medicines.
6. A follow-up plan for the patients to ensure long-term care.
Development of mDSS
An expert group comprising cardiologists and endocrinologists
designed a contextual clinical management guideline for
hypertension and diabetes mellitus for the primary care
physicians. Subsequently the guidelines were converted into
mDSS by a software developer (Data Template Infotech Private
Limited, Bangalore). The essential features of the mDSS
(Table S3) and the design of the sequence of the user
interfaces (Figure S1) were determined with the help of the
developer and a prototype mDSS was developed. The mDSS
initially required 36 data points for each patient to generate an
individualized clinical management plan. The prototype was
tested by developers by their in-house software testing team
for errors in software codes and logic given to them. The
prototype was further tested by 2 researchers (V.S.A., D.J.) for
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the accuracy of the treatment plan generated using a range of
possible scenarios. After ﬁxing the errors, the prototype was
ﬁeld tested (user acceptance testing) with the help of two NCCs
at the clinics for 2 weeks to elicit feedback on ease of use,
interface and layout, and difﬁculties in comprehending inputs/
outputs of the software. Incorporating this feedback, mDSS
version 1.0 was released for deployment in 5 CHCs. At the end
of 1 month, the NCCs reported that the Medical Ofﬁcers may
not co-operate with them longer, because the high number of
data elements required to be entered into the mDSS was
chocking the patient ﬂow. The expert group met again and
decided to simplify the clinical management guideline. An
updated mDSS (version 2.0) was released with 23 data points
for the use of NCCs. Subsequently, 7 minor iterations were
made to the mDSS, and the most recent version in use is
version 2.1.5. A schematic diagram on the process followed in
the development of mDSS is shown in Figure 1.
The newly developed intervention was implemented in 5
CHCs with minor modiﬁcations in their workﬂow and was fully
integrated into the routine care with least discomfort to the
healthcare team or patients. Patients coming to the CHC ﬁrst
approached the registration counter where they received an
outpatient card that recorded their name, age, and address.
All patients above the age of 30 were directed to the NCC for
screening of hypertension/diabetes mellitus. The NCC
assessed their demographic details, medical history, anthro-
pometry, and blood pressure. Additionally, fasting plasma
glucose values were recorded for people with diabetes
mellitus. Subsequently NCC fed this information into the
mDSS tool to generate a personalized patient management
plan. The mDSS-generated patient management plan was
then recorded onto a custom-made NCD card and handed
over to the patient. The patient then approached the medical
ofﬁcer along with the NCD card. The medical ofﬁcer either
approved the management plan or modiﬁed/rejected it
according to his/her clinical judgment and recorded it in
the NCD card with the reason for disagreement. The patient
was then directed to the NCC, who then added the decisions
of the doctor to the electronic patient record generated in the
mDSS for future reference. The NCC then provided health
education/counseling to the patients on drug intake, compli-
ance, tobacco cessation, healthy diet, physical activity,
moderation in alcohol use, and a follow-up plan for future
visits to the clinic (Figure 2).
Opportunistic screening resulted in 4 groups: (1) Screen
positive subjects for hypertension; (2) Screen positive
subjects for diabetes mellitus; (3) People with previous
diagnosis of hypertension/diabetes mellitus or follow-up
cases; and (4) Screen negative subjects. At the time of
opportunistic screening, screen positive hypertension
Figure 1. Steps in the development process of mDSS. mDSS indicates mobile phone–based clinical
decision support system.
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subjects were advised to re-visit for conﬁrmatory diagnosis or
put on hypertension management immediately (if blood
pressure was >160/100) or referred to higher-level centers
(in case of hypertension urgency/emergency), depending on
the blood pressure level and comorbidities. Screen positive
diabetes mellitus subjects were advised to revisit the clinic in
fasting state for conﬁrmatory laboratory diagnosis. After
conﬁrmatory diagnosis of diabetes mellitus, the NCC gener-
ated a management plan using mDSS for the concurrence of
the Medical Ofﬁcer. People with known hypertension/dia-
betes mellitus or follow-up cases visiting the CHC approached
the NCC directly. Modiﬁcation in their medication dosages
were decided with the help of mDSS, which calculated optimal
dose depending upon the clinical and laboratory values during
that visit. People identiﬁed in the stage of prehypertension/
prediabetes mellitus during screening were provided lifestyle
counseling by the NCC.
Effect of the Intervention on Outcome Indicators
After the complete rollout of the intervention on December 1,
2012 at 5 CHCs, a total of 132 370 patients attended these
centers over the next 21 months until August 31, 2014. Of
these, 22 009 (16.6%) subjects aged 30 years or above were
eligible for opportunistic screening (Table 1). On screening
the eligible group, 6797 (31%) subjects were identiﬁed to have
either hypertension or diabetes mellitus, or both. Among
these patients, nearly half (3391/6797) were diagnosed with
hypertension/diabetes mellitus for the ﬁrst time by
opportunistic screening. Enrollment was a continuous process
throughout the intervention period, and the duration of follow-
up varied across participants.
Impact on Blood Pressure Level Among Subjects
With Hypertension
A total of 6016 subjects with hypertension were enrolled,
including 3152 (52%) newly detected by opportunistic screening.
Among people with hypertension, the longest follow-up data
(18 months) were available for 759 subjects, while only baseline
values were available for 292 subjects who enrolled towards the
end of the intervention. The mean SBP at baseline was
146.1 mm Hg (95% CI: 145.7, 146.5), with newly diagnosed
subjects having a higher SBP at baseline (149.1 mm Hg, 95% CI:
148.6, 149.7) as compared to subjects with known hypertension
(143.0 mm Hg, 95% CI: 142.4, 143.6). During intervention,
major reduction in SBP (12.9 mm Hg, 95% CI:13.2,12.7)
occurred during the initial 3 months of enrollment, which was
sustained at 18 months (14.6 mm Hg, 95% CI: 15.3,
13.8). Though the 2 groups reached similar blood pressure
levels at 12 months, they tended to diverge at further follow-up
with higher mean SBP among newly diagnosed subjects as
compared to people with known hypertension (Figure 3). The
reductions observed in SBP levels in both of the groups at all the
time points, in comparison with their baseline estimates, were
statistically signiﬁcant even after adjusting for age, sex, and CHC
(Table 2) and were signiﬁcantly higher among newly diagnosed
subjects throughout 18 months of follow-up.
Figure 2. Workﬂow at the CHCs during the intervention. CHCs indicates Community Health Centers; mDSS mobile phone–based clinical
decision support system; NCD, noncommunicable diseases; OPD, outpatient department.
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Our study had individuals with only hypertension
(N=5281), only diabetes mellitus (N=781), as well as those
comorbid with these conditions (N=735). The change in SBP
level in both diagnoses groups (people with only hypertension
versus those with hypertension and diabetes mellitus) were
also statistically signiﬁcant even after adjusting for age, sex,
and CHC. However, the SBP change observed was signiﬁ-
cantly higher among people with hypertension alone until the
ninth month of follow-up, which tended to overlap during
longer follow-up (results not shown).
Similarly, statistically signiﬁcant reduction in DBP
(7.1 mm Hg; 95% CI: 7.3, 6.9) occurred during the
initial 3-month period from a mean baseline level of
89.52 mm Hg (95% CI: 89.33, 89.72) with an overall change
of 7.7 mm Hg (95% CI: 8.0, 7.3) at 18 months of follow-
up. Individuals who had newly diagnosed hypertension
experienced a larger reduction in mean DBP (10.2 mm Hg;
95% CI: 10.8, 9.7) compared to individuals with known
hypertension (5.6 mm Hg; 95% CI: 6.2, 5.0) at
18 months. The 2 groups reached similar blood pressure
levels at 6-month follow-up and were similar at remaining
follow-up points (Figure 4). The reductions observed in DBP
levels in both of the groups at all the time points, in
comparison with their baseline estimates, were signiﬁcant
even after adjusting for age, sex, and CHC (Table 2) and were
signiﬁcantly higher among newly diagnosed subjects through-
out 18 months of follow-up. The change in DBP level in both
diagnoses groups (people with hypertension alone versus
those with both hypertension and diabetes mellitus) was
statistically signiﬁcant even after adjusting for age, sex, and
CHC. In addition, the change in DBP was signiﬁcantly higher
among people with hypertension alone throughout the follow-
up (results not shown).
Impact of the Intervention on Blood Glucose
Levels of Diabetes Mellitus Patients
A total of 1516 participants with diabetes mellitus were
enrolled in the study, of which 450 (30%) subjects were
newly detected by opportunistic screening. Among people
with diabetes mellitus, longest follow-up data were available
for 293 subjects (18 months), while only baseline values
were available for 114 subjects who enrolled toward the
end of intervention. The mean fasting blood glucose at
baseline was 177.9 mg/dL (95% CI: 175.8, 180.0), with the
newly diagnosed subjects having a higher glucose level at
baseline (185.1 mg/dL, 95% CI: 181.2, 188.9) as compared
to subjects with known diabetes mellitus (174.8 mg/dL,
Table 1. Proportion of Known and New Subjects With Hypertension/Diabetes Mellitus Detected as a Result of Introducing
Opportunistic Screening
Name of
the CHC
Number of
Patients
Attended the CHC
Eligible Group
for Screening
Subjects With
Hypertension
Subjects With
Diabetes Mellitus
Subjects With Both
Hypertension &
Diabetes Mellitus
% of Subjects With
Hypertension or
Diabetes Mellitus by
Opportunistic
Screening
Known
Newly
Detected Known
Newly
Detected Known
Newly
Detected Known
Newly
Detected
Kunihar 34 633 4984 534 598 85 200 54 154 41.4 58.6
Syri 12 494 1824 173 330 12 28 8 37 32.8 67.2
Dharampur 28 564 3847 665 255 51 19 55 47 70.6 29.4
Dharlagarh 22 649 3533 414 353 24 22 14 24 53.1 46.9
Nalagarh 34 030 7821 1161 798 82 258 74 268 49.9 50.1
Total 132 370 22 009 2947 2334 254 527 205 530 50.1 49.9
CHC indicates Community Health Center.
Figure 3. Change in mean systolic blood pressure level during
18 months of follow-up; plotted with 95% conﬁdence interval.
Dashed black line: mean systolic blood pressure level among
known cases during 18 months of follow-up. Solid black line:
mean systolic blood pressure level among newly diagnosed
cases during 18 months of follow-up.
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95% CI: 172.3, 177.3). The reduction in mean FPG level
observed during 18 months of follow-up was 50.2 mg/dL
(95% CI: 54.7, 45.7) with major reduction occurring in
the ﬁrst 3 months of follow-up. The reduction in FPG level
was impressive and substantial in comparison to baseline
levels even after adjusting for age, sex, and CHC (Table 3).
Newly detected subjects with diabetes mellitus had a
greater reduction in their mean FPG level (63.7 mg/dL;
95% CI: 72.2, 55.3) than those with known disease
(44.7 mg/dL; 95% CI: 50.0, 39.4). The 2 groups
varied signiﬁcantly in their mean FPG level during the entire
follow-up period, except during their third month of follow-
up, with signiﬁcantly higher mean FPG level among those
known to have diabetes mellitus at recruitment (Figure 5).
The 2 groups differed in their reduction in FPG level
throughout the follow-up, even after adjusting for age, sex,
and CHC. The reduction in FPG level in both diagnoses
groups (people with diabetes mellitus alone versus those
with both hypertension and diabetes mellitus), when
adjusted for age, sex, and CHC, was statistically signiﬁcant,
with higher reduction among people with diabetes mellitus
alone throughout the follow-up, except during third month
of follow-up (results not shown).
We also analyzed the pattern of missing data for all of the 5
CHCs. Given that participants could enroll at any time point
throughout the intervention period, the individuals recruited in
the ﬁrst few months of the program had the most follow-up
data compared to those recruited during the later months.
Intermittent missing data pattern was not observed, indicating
overall good follow-up and retention in the program. We also
had limited covariate data on the participants in the study,
and therefore it was reasonable to make these assumptions
consistent with the generalized estimating equations model.Ta
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Figure 4. Change in mean diastolic blood pressure level
during 18 months of follow-up; plotted with 95% conﬁdence
interval. Dashed black line: mean diastolic blood pressure level
among known cases during 18 months of follow-up. Solid black
line: mean diastolic blood pressure level among newly diag-
nosed cases during 18 months of follow-up.
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Agreement With mDSS and Supply of Medicines
We analyzed 100 consecutive prescriptions from each CHC and
found that 73% of them were in agreement with the mDSS
suggestion. The major reason for deviation was unavailability of
medicine at the pharmacies of CHCs. We also assessed the
availability ofmedicines at the pharmacy, for December 2012 to
June 2013 (atenolol: 9900; enalapril: 12 200; amlodipine:
3000; metformin: 30 700), and found that medicine supply was
grossly insufﬁcient. Hence, close to 80% of the patients were
relying on out-of-pocket spending for medicines.
Discussion
To the best of our knowledge, this study is the ﬁrst published
report from India about the development and evaluation of an
mDSS-enabled intervention through a NCC for hypertension
and diabetes mellitus care in primary care settings. This work
demonstrates the feasibility of task sharing of physician duties
with an mDSS-empowered NCC for management of hyperten-
sion and diabetes mellitus in current primary care settings of
India. Furthermore, this strategy led to an impressive and
signiﬁcant reduction in blood pressure and blood glucose levels
that persisted up to 18 months of follow-up.
The core activities of the intervention were opportunistic
screening and evidence-based clinical management. The
results from this study reinforce the concerns about a huge
unmet need for hypertension and diabetes mellitus care in
primary care settings. Close to a third of the outpatients
above 30 years of age were detected with hypertension and/
or diabetes mellitus. Half of these were newly diagnosed
cases, which emphasizes the importance of opportunistic
screening. It also opens a new window of opportunity for
effective screening and management of hypertension and
diabetes mellitus in primary care settings with innovative
strategies that may be instrumental in surmounting the huge
burden of cardiovascular diseases and its risk factors in the
country.
The large reductions in systolic blood pressure observed in
this study were similar to some of the previous studies that
reported ﬁndings from nurse-led interventions for patients
with hypertension in the developed country settings.13,14
Furthermore, our observations are consistent with other large
multifactorial health system interventions (comprising patient
registry, evidence-based guidelines, quality performance met-
rics, medical assistant, and single pill combination therapy)
experiments in the United States such as the Kaiser
Permanente Northern California Hypertension program, which
resulted in near doubling of hypertension control rates from
43.6% in 2001 to 87.1% in 2011.15 In India, a randomized trial
of a computer-based clinical decision support tool for
hypertension care at primary care setting has been found to
Table 3. Mean Change in Fasting Plasma Glucose Over Time mg/dL (95% CI)
Time Overall (Unadjusted) Overall (Adjusted for Age, Sex, and CHC) New Cases* Known Cases*
3 months 31.5† (34.1, 28.9) 27.4† (30.2, 24.6) 36.1† (41.4, 30.7) 24.0† (27.3, 20.7)
6 months 42.5† (45.2, 39.8) 38.0† (41.2, 34.9) 51.9† (57.4, 46.3) 32.4† (36.2, 28.6)
9 months 44.6† (47.4, 41.7) 39.7† (43.0, .36.3) 57.4† (63.4, 51.3) 32.4† (36.3, 28.5)
12 months 49.3† (52.0, 46.3) 44.4† (47.8, 41.0) 57.5† (63.6, 51.3) 39.0† (43.0, 35.0)
15 months 46.8† (50.3, 43.3) 41.5† (45.1, 37.8) 57.2† (63.5, 51.0) 34.9† (39.2, 30.6)
18 months 50.2† (54.7, 45.7) 44.3† (48.3, 40.3) 58.57† (65.7, 51.5) 38.7† (43.4, 34.0)
Constant 177.9† (175.8, 180.0) 182.1† (176.2, 188.1) 175.5† (169.2, 181.9)
N 1516 1516 459 1057
CHC indicates Community Health Center.
*Results from the interaction model.
†P<0.001.
Figure 5. Change in mean fasting blood glucose level during
18 months of follow-up; plotted with 95% conﬁdence interval.
Dashed black line: mean fasting blood glucose level among known
cases during 18 months of follow-up. Solid black line: mean
fasting blood glucose level among newly diagnosed cases during
18 months of follow-up.
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be efﬁcacious and cost-effective with an estimated reduction
of 10.1 mm Hg of SBP in the intervention arm.16 Another
recent community health worker–led trial of cardiovascular
risk reduction intervention in rural India and Tibet also
demonstrated a reduction of 11.8 mm Hg of SBP in the
intervention arm in a setting where people were not accessing
follow-up care from primary care facilities, even after being
identiﬁed to be at high risk of cardiovascular diseases.17
We observed impressive and substantial reduction in mean
blood glucose levels among diabetes mellitus patients. The
change observed was even higher than those reported in
meta-analysis of quality improvement strategy trials in
diabetes mellitus care from developed countries.18,19 The
baseline FPG levels among the diabetes mellitus group were
very high and this could be the reason for the large reduction
in fasting glucose values. These results have important
implications for low-and-middle income countries where
primary care facilities seldom carry out an opportunistic
screening program for hypertension and diabetes mellitus and
often undertreat such patients due to lack of structured
instructions or inadequate training and overcrowding. In
addition, physicians often pay scant attention to advising
patients on behavior modiﬁcations and compliance with
medications that are essential for managing these diseases.
This intervention has great potential for scalability in India as
well where the national NCD program aims to establish a NCD
clinic in CHCs, with the appointment of a Medical Ofﬁcer,
nurse, and counselor, which has high synergy to implement
m-Power Heart model intervention.
Though it is difﬁcult to dissect out the effect of individual
components of the intervention, qualitative exploration
revealed a major role for additional personnel—a trained
NCC deployed at the clinics—in the intervention. The new
NCCs partially or fully addressed the personnel shortage at
the clinics of the hospitals and had a high level of acceptance
from Medical Ofﬁcers as well as patients as caregivers.
The mDSS tool also had a major role in promoting
evidence-based practices at CHCs and helped in overcoming
the “clinical inertia.” It helped the healthcare team to conduct
comprehensive patient evaluation in a structured manner and
also served as an electronic health record. The intervention
also highlights the utility of technology in primary care
settings for NCD risk factors management. Several studies
carried out earlier in developed nations provide support to the
utility of technology in improving health outcomes in diabetes
mellitus and hypertension care.20,21
There were certain limitations of this intervention. A
randomized control would be the “gold standard” for evalu-
ation. Given the previous evidences of beneﬁts that have been
noted both for task shifting by NCCs and the limited evidence
on an internet technology–based decision support system, we
believed a demonstration project would be the best design to
demonstrate feasibility, potential for scale-up, and mimic real-
world health systems. Furthermore, due to limited resources
available for the study and insistence of the health authorities
to involve all the CHCs (due to ethical reasons), no control
arm was available for comparison. Given the volume of
patients screened and enrolled in a routine clinic, there were
practical difﬁculties in obtaining detailed information on
potential confounders such as duration of prior medication
use, types of medication and comorbidities, and integrating all
such information into the DSS. Therefore, the ﬁndings could
have resulted from some unmeasured confounding in the
regression models. In addition, the observations on the
interaction effect of disease groups and time should be
interpreted with caution, because of the large differences in
sample size between subgroups.
The limited number of CHCs involved in the development
and evaluation of the intervention could be another drawback,
as the developed intervention might require further cus-
tomization or modiﬁcation for scaling-up in other Indian states
and other international settings. Given our limited resources,
we did not evaluate health outcomes such as stroke,
myocardial infarction, or death. The major strength of our
study is the NCC, as the Government of India in its action plan
for NCDs has sanctioned a nurse to assist physicians at NCD
clinics to be located at CHC. This study attests to the utility of
those extra personnel. The second major strength is the low
cost of developing the mDSS (data not shown).
Conclusions
Our study demonstrates the feasibility of nurse-facilitated,
mDSS-enabled intervention for hypertension and diabetes
mellitus care in the primary care setting in India. Though the
results from this study offer great potential for scale-up in the
public health system in developing countries, more research
needs to be carried out to test its real-world efﬁcacy in
randomized control trials.
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Table S1. Clinical Management Guideline for hypertension 
 
 
Clinical parameters If Age<55 If Age≥55 Messages 
if (SBP≥140<160) OR 
(DBP≥90<100) 
Life Style Advices, If on medication, 
continue 
Life Style Advices, If on medication, 
continue  
if ((SBP≥160) OR 
(DBP≥100)) AND (NO co-
morbidities- 
COPD/ASTHMA, 
MYOCARDIAL 
INFARCTION, 
RENAL/LIVER FAILURE, 
PVD, HEART BLOCK, 
DIABETES) 
1st: ACEi/ARB or CCB 
2nd: ACEi/ARB + CCB or 
ACEi/ARB+Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
1st: CCB or Diuretics 
2nd: ACEi/ARB + CCB or CCB + 
Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
If on medication, consider increasing the 
dose up or adding 2nd/3rd line drug. 
if ((SBP≥160) OR (DBP 
≥100)) AND 
(COPD/ASTHMA) 
1st: CCB 
2nd: CCB + ACEi/ARB  or CCB + 
Diuretic 
3rd: ACEi/ARB + CCB + Diuretic 
1st: CCB 
2nd: CCB + ACEi/ARB  or CCB + 
Diuretic 
3rd:ACEi/ARB + CCB + Diuretic 
Avoid BB. If on medication, consider 
increasing the dose up or adding 2nd/3rd 
line drug. 
if ((SBP≥140) OR (DBP 
≥90)) AND (DIABETES) 
1st: ACEI/ARB + ASA 
2nd: ACEi/ARB + CCB or ACEi/ARB 
+ Diuretic along with ASA 
3rd: ACEi/ARB + CCB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or BB along 
with ASA 
1st: CCB (PREFERRED) or ASA 
OR ACEi/ARB along with ASA 
2nd: ACEi/ARB + CCB or 
ACEi/ARB + Diuretic  along with 
ASA 
3rd: ACEi/ARB + CCB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or BB along 
with ASA 
If on medication, consider titrating the 
dose up or adding 2nd/3rd line drug. 
ASA Contraindicated if SBP>160 or 
DBP>100 or having gastritis or Aspirin 
Allergy 
if ((SBP≥140) OR (DBP 
≥90)) AND 
(MYOCARDIAL 
INFRACTION) 
1st: BB + ASA 
2nd: BB + CCB or BB + ACEi/ARB 
along with ASA 
3rd: BB + ACEi/ARB + 
CCB/Diuretics along with ASA 
1st: BB + ASA 
2nd: BB + CCB or BB + ACEi/ARB 
along with ASA 
3rd: BB + ACEi/ARB + 
CCB/Diuretics along with ASA 
If on medication, consider titrating the 
dose up or adding 2nd/3rd line drug. 
ASA Contraindicated if SBP>160 or 
DBP>100 or having gastritis or Aspirin 
Allergy 
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 Clinical parameters If Age<55 If Age≥55 Messages 
if ((SBP≥140) OR (DBP 
≥90)) AND (RENAL/LIVER 
FAILURE {CREATININE> 
3mg}) 
1st: CCB  
2nd: CCB + Diuretic 
3rd: ADD Alpha Blocker or BB or 
Other Diuretic 
1st: CCB  
2nd: CCB + Diuretic 
3rd: ADD Alpha Blocker or BB or 
Other Diuretic 
 
Avoid ACEi/ARB. If on medication, 
consider titrating the dose up or adding 
2nd/3rd line drug. 
if ((SBP≥140) OR (DBP 
≥90)) AND ((PVD)) 
1st: CCB + ASA 
2nd: CCB + ACEi/ARB or CCB + 
Diuretic along with ASA 
3rd: CCB + ACEi/ARB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or Other 
Diuretic along with ASA 
1st: CCB + ASA 
2nd: CCB + ACEi/ARB or CCB + 
Diuretic along with ASA 
3rd: CCB + ACEi/ARB + Diuretic 
along with ASA 
4th: Add Alpha Blocker or Other 
Diuretic along with ASA 
Avoid BB. If on medication, consider 
titrating the dose up or adding 2nd/3rd 
line drug. ASA Contraindicated if 
SBP>160 or DBP>100 or having 
gastritis or Aspirin Allergy 
if ((SBP≥140) OR (DBP 
≥90)) AND ((HEART 
BLOCK)) 
1st: ACEi/ARB 
2nd: ACEi/ARB + CCB or ACEi/ARB 
+ Diuretic  
3rd: ACEi/ARB + CCB + Diuretic 
4th: Add Alpha Blocker or Other 
Diuretic 
1st: CCB (PREFERRED) OR 
ACEi/ARB 
2nd:CCB + ACEi/ARB or CCB + 
Diuretic 
3rd: CCB + ACEi/ARB + Diuretic 
4th: Add Alpha Blocker or Other 
Diuretic 
Verify Again. DILTIAZEM & 
VERAPAMIL & BB Contraindicared. If 
on medication, consider titrating the dose 
up or adding 2nd/3rd line drug. 
if DBP≥130 
Hypertensive emergency. Refer the 
patient immediately  Hypertensive emergency. Refer the patient immediately  
ACEi: Angiotensin Converting Enzyme Inhibitors; ARB: angiotensin receptor blockers; ASA: acetylsalicylic acid; BB: Beta Blockers; CCB: 
Calcium Channel blockers; COPD: Chronic Obstructive Pulmonary Disease; DBP: Diastolic Blood Pressure; PVD: Peripheral Vascular Disease; 
SBP: Systolic Blood Pressure 
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Table S2. Clinical Management Guideline for Diabetes Mellitus 
FAIR CONTROL, INSUFFICIENT 
CONTROL= 
((FPG<110) AND (PP=200-300)) OR ((FPG =110 - 130) AND (PP=140-300)) OR 
(((FPG>130) AND (PP<=200)) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI <= 23 1 Unit SU (5mg Glibenclamide  OR   80mg Gliclazide) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI > 23 500mg Metformin 
If (1 or 2 OHA, NOT AT MAXIMUM DOSE is 
in USE) AND (NO INSULIN USE) 
Consider 1 UNIT increment ( SU { 5mg Glibenclamide, OR 80mg Gliclazide}, OR  500mg 
Metformin, OR 15mg Pioglitzone) 
If (2 OHA AT MAXIMUM DOSE IS IN USE) 
AND (NO INSULIN USE) 
ADD 3rd OHA (500mg Metformin   OR   SU{ 5mg Glibenclamide,   OR   80mg Gliclazide}    
OR    15mg Pioglitazone) 
If (3 OHA AT MAXIMUM DOSE IS IN USE) 
AND (NO INSULIN USE) Start Insulin-Bedtime NPH Dose (10 units or 0.2U/kg/day). MESSAGE* 
POOR CONTROL, VERY POOR 
CONTROL= 
((FPG>130) AND (PP=201-300))  OR ((FPG<110) AND (PP≥301))  OR  
 ((FPG=110-130) AND (P≥301))  OR ((FPG>130) AND (PP≥301)) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI <= 23 2 Unit SU (10mg Glibenclamide  OR  160mg Gliclazide) 
If (No OHA USE) AND (No INSULIN USE) 
AND BMI > 23 1000mg Metformin 
If (1 or 2 OHA, NOT AT MAXIMUM DOSE is 
in USE) AND (NO INSULIN USE) 
Consider 2 Unit increment (2 of the same or 2 different) ( SU { 10mg Glibenclamide  OR  160mg 
Gliclazide} OR 1000mg Metformin   OR   30mg Pioglitzone) 
If (2 OHA AT MAXIMUM DOSE IS IN USE) 
AND (NO INSULIN USE) 
ADD 1 Unit addition of 3rd OHA (500mg Metformin   OR   SU { 5mg Glibenclamide  OR   80mg 
Gliclazide}    OR   15mg Pioglitazone) 
If (3 OHA AT MAXIMUM DOSE IS IN USE) 
AND (NO INSULIN USE) Insulin-Bedtime NPH Dose (10 units or 0.2U/kg/day).  MESSAGE* 
IF (INSULIN IN USE) AND (FPG<=70) Reduce NPH dose. MESSAGE* 
IF (INSULIN IN USE) AND (FPG>120) Increase NPH dose up to .5U/kg/day. MESSAGE* 
*MESSAGE: Review FPG after 1 week (Target FPG: 80-110).  If current insulin dose is @ .5U/kg, add AM NPH (10 units or 0.2U/kg/day), 
Maximum NPH upto 20 Units only. If target not achieved, shift to PM Insulin two times daily 
BMI: Body Mass Index; FPG: Fasting Plasma glucose; NPH: Neutral Protamine Hagedorn; OHA: Oral Hypoglycaemic Agents; PP: Post 
Prandial glucose 
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Table S3. Essential Features of the mDSS 
 
 
1. Generation of electronic patient records in the mobile phone and in a central database. 
2. Clinical risk score for diagnosing diabetes 
3. Generation of personalized management plan for hypertension 
4. Generation of personalized management plan for diabetes 
5. Generation of serial data to provide continuity of care during follow-up visits 
6. Quality assurance checks 
7. Ability to export to statistic software packages for analysing temporal trends  
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Figure S1. Sequence of user interfaces in the mDSS. 
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